UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 89

Sortiert nach

The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia

Scientific reports, 2020-12, Vol.10 (1), p.21420-21420, Article 21420

2020

Link zum Volltext

Verfügbarkeit prüfen

Cyclic Peptides for Effective Treatment in a Long-Term Model of Graves Disease and Orbitopathy in Female Mice

Endocrinology (Philadelphia), 2017-07, Vol.158 (7), p.2376-2390

2017

Link zum Volltext

Verfügbarkeit prüfen

The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times

PloS one, 2013-08, Vol.8 (8), p.e71193

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells

Molecular pharmacology, 2013-07, Vol.84 (1), p.25-40

2013

Link zum Volltext

Verfügbarkeit prüfen

Review of Mouse Models of Graves’ Disease and Orbitopathy—Novel Treatment by Induction of Tolerance

Clinical Reviews in Allergy & Immunology, 2017-04, Vol.52 (2), p.182-193

2017

Link zum Volltext

Verfügbarkeit prüfen

Prolonged TSH Receptor A Subunit Immunization of Female Mice Leads to a Long-Term Model of Graves' Disease, Tachycardia, and Cardiac Hypertrophy

Endocrinology (Philadelphia), 2015-04, Vol.156 (4), p.1577-1589

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of glycoprotein VI and platelet adhesion on atherosclerosis—A possible role of fibronectin

Journal of molecular and cellular cardiology, 2010-09, Vol.49 (3), p.532-542

2010

Link zum Volltext

Verfügbarkeit prüfen

The Scavenger Receptor CD68 Regulates Platelet Mediated Oxidized Low-Density Lipoprotein (oxLDL) Deposition in Atherosclerotic Vessels at an Early Stage of Atherosclerosis in LDLR -/- /ApoBec -/- Mice

Cellular physiology and biochemistry, 2019, Vol.52 (4), p.681-695

2019

Link zum Volltext

Verfügbarkeit prüfen

Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans

Circulation (New York, N.Y.), 2011-05, Vol.123 (17), p.1891-1899

2011

Link zum Volltext

Verfügbarkeit prüfen

The Platelet Anaphylatoxin Receptor C5aR1 (CD88) Is a Promising Target for Modulating Vessel Growth in Response to Ischemiaa

TH open : companion journal to thrombosis and haemostasis, 2023-10, Vol.7 (4), p.e289-e293

2023

Link zum Volltext

Verfügbarkeit prüfen

Effect of the oxLDL Binding Protein Fc-CD68 on Plaque Extension and Vulnerability in Atherosclerosis

Circulation research, 2011-03, Vol.108 (6), p.695-703

2011

Link zum Volltext

Verfügbarkeit prüfen

PET/CT and MR imaging biomarker of lipid-rich plaques using [64 Cu]-labeled scavenger receptor (CD68-Fc)

International journal of cardiology, 2014-11, Vol.177 (1), p.287-291

2014

Link zum Volltext

Verfügbarkeit prüfen

ADPase CD39 Fused to Glycoprotein VI‐Fc Boosts Local Antithrombotic Effects at Vascular Lesions

Journal of the American Heart Association, 2017-08, Vol.6 (8), p.n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

Minimal Collagen-Binding Epitope of Glycoprotein VI in Human and Mouse Platelets

Biomedicines, 2023-02, Vol.11 (2), p.423

2023

Link zum Volltext

Verfügbarkeit prüfen

EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction

Thrombosis and haemostasis, 2009-04, Vol.101 (4), p.682

2009

Link zum Volltext

Verfügbarkeit prüfen

Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial

TH open : companion journal to thrombosis and haemostasis, 2020-10, Vol.4 (4), p.e393-e399

2020

Link zum Volltext

Verfügbarkeit prüfen

Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke

Heart international, 2016-01, Vol.11 (1), p.e10-e16

2016

Link zum Volltext

Verfügbarkeit prüfen

Differential Inhibition of Human Atherosclerotic Plaque–Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies

Journal of the American College of Cardiology, 2015-06, Vol.65 (22), p.2404-2415

2015

Link zum Volltext

Verfügbarkeit prüfen

Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its Inhibition of Atherosclerotic Plaque- and Collagen-Induced Platelet Activation

JACC. Basic to translational science, 2016-04, Vol.1 (3), p.131-142

2016

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of foam cell formation using a soluble CD68-Fc fusion protein

Journal of molecular medicine (Berlin, Germany), 2010-09, Vol.88 (9), p.909-920

2010

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of ABCG1 protein attenuates arteriosclerosis and endothelial dysfunction in atherosclerotic rabbits

Heart international, 2012, Vol.7 (2), p.e12-e12

2012

Link zum Volltext

Verfügbarkeit prüfen

Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo

Thrombosis and haemostasis, 2006-05, Vol.95 (5), p.763

2006

Link zum Volltext

Verfügbarkeit prüfen

Evidence for Calcineurin-mediated Regulation of SERCA 2a Activity in Human Myocardium

Journal of molecular and cellular cardiology, 2002-03, Vol.34 (3), p.321-334

2002

Link zum Volltext

Verfügbarkeit prüfen

Oral Presentation No. 64 Elevated soluble glycoprotein VI, a specific predictor of bleeding risk in patients with chronic coronary syndromes undergoing percutaneous coronary intervention

Cardiovascular research, 2022-10, Vol.118 (Supplement_2)

2022

Link zum Volltext

Verfügbarkeit prüfen

Plasma Soluble Glycoprotein VI, Platelet Function, Bleeding, and Ischemic Events in Patients Undergoing Elective Percutaneous Coronary Intervention

Thrombosis and haemostasis, 2024-04, Vol.124 (4), p.297

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(81)

Publikationsform

Sprache

Englisch
(79)
Japanisch
(16)
Deutsch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(50)
Life Sciences & Biomedicine
(46)
Humans
(43)
Animals
(32)
Cardiovascular System & Cardiology
(30)
Cardiac & Cardiovascular Systems
(22)
Biological And Medical Sciences
(21)
Mice
(20)
Medical Sciences
(18)
Peripheral Vascular Disease
(17)
Female
(16)
Male
(16)
Cardiology. Vascular System
(12)
Glycoprotein Vi
(12)
Adult
(11)
Atherosclerosis
(11)
Fundamental And Applied Biological Sciences. Psychology
(10)
Heart Failure
(10)
Hematology
(10)
Platelets
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia

Cyclic Peptides for Effective Treatment in a Long-Term Model of Graves Disease and Orbitopathy in Female Mice

The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times

Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells

Review of Mouse Models of Graves’ Disease and Orbitopathy—Novel Treatment by Induction of Tolerance

Prolonged TSH Receptor A Subunit Immunization of Female Mice Leads to a Long-Term Model of Graves' Disease, Tachycardia, and Cardiac Hypertrophy

Impact of glycoprotein VI and platelet adhesion on atherosclerosis—A possible role of fibronectin

The Scavenger Receptor CD68 Regulates Platelet Mediated Oxidized Low-Density Lipoprotein (oxLDL) Deposition in Atherosclerotic Vessels at an Early Stage of Atherosclerosis in LDLR -/- /ApoBec -/- Mice

Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans

The Platelet Anaphylatoxin Receptor C5aR1 (CD88) Is a Promising Target for Modulating Vessel Growth in Response to Ischemiaa

Effect of the oxLDL Binding Protein Fc-CD68 on Plaque Extension and Vulnerability in Atherosclerosis

PET/CT and MR imaging biomarker of lipid-rich plaques using [64 Cu]-labeled scavenger receptor (CD68-Fc)

ADPase CD39 Fused to Glycoprotein VI‐Fc Boosts Local Antithrombotic Effects at Vascular Lesions

Minimal Collagen-Binding Epitope of Glycoprotein VI in Human and Mouse Platelets

EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction

Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial

Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke

Differential Inhibition of Human Atherosclerotic Plaque–Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies

Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its Inhibition of Atherosclerotic Plaque- and Collagen-Induced Platelet Activation

Inhibition of foam cell formation using a soluble CD68-Fc fusion protein

Overexpression of ABCG1 protein attenuates arteriosclerosis and endothelial dysfunction in atherosclerotic rabbits

Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo

Evidence for Calcineurin-mediated Regulation of SERCA 2a Activity in Human Myocardium

Oral Presentation No. 64 Elevated soluble glycoprotein VI, a specific predictor of bleeding risk in patients with chronic coronary syndromes undergoing percutaneous coronary intervention

Plasma Soluble Glycoprotein VI, Platelet Function, Bleeding, and Ischemic Events in Patients Undergoing Elective Percutaneous Coronary Intervention

Suchergebnisse filtern